Monitoring phosphodiesterase-4 inhibitors using liquid chromatography/ (tandem) mass spectrometry in sports drug testing

Rapid Communications in Mass Spectrometry

Volumn 27, Issue 9, 2013, Pages 993-1004

  Thevis, Mario ^a,b   Krug, Oliver ^a,b   Schänzer, Wilhelm ^a  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

^b European Monitoring Center for Emerging Doping Agents   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ASSAYS; BIOMOLECULES; DIAGNOSIS; DRUG PRODUCTS; ENZYMATIC HYDROLYSIS; ESTERS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH PRESSURE LIQUID CHROMATOGRAPHY; IONS; MAMMALS; MASS SPECTROMETRY; SPORTS;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; DOPING CONTROL; DRUG TESTING; LC-MS-MS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; PDE4 INHIBITOR; PHOSPHODIESTERASE-4; PHOSPHODIESTERASES; PRODUCT IONS;

METABOLITES;

EID: 84876278773     PISSN: 09514198     EISSN: 10970231     Source Type: Journal    
DOI: 10.1002/rcm.6539     Document Type: Article

References (25)

1. R. I. Tennen, E. Michishita-Kioi, K. F. Chua,. Finding a target for resveratrol. Cell 2012, 148, 387.
2. S. J. Park, F. Ahmad, A. Philp, K. Baar, T. Williams, H. Luo, H. Ke, H. Rehmann, R. Taussig, A. L. Brown, M. K. Kim, M. A. Beaven, A. B. Burgin, V. Manganiello, J. H. Chung,. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012, 148, 421.
3. C. A. Blum, J. L. Ellis, C. Loh, P. Y. Ng, R. B. Perni, R. L. Stein,. SIRT1 modulation as a novel approach to the treatment of diseases of aging. J. Med. Chem. 2011, 54, 417.
4. L. Pages, A. Gavalda, M. D. Lehner,. PDE4 inhibitors: a review of current developments (2005-2009). Exp. Opin. Ther. Patents 2009, 19, 1501.
5. A. Hatzelmann, E. J. Morcillo, G. Lungarella, S. Adnot, S. Sanjar, R. Beume, C. Schudt, H. Tenor,. The preclinical pharmacology of roflumilast - a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pul. Pharmacol. Ther. 2010, 23, 235.
6. K. F. Rabe,. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br. J. Pharmacol. 2011, 163, 53.
7. P. Salari, M. Abdollahi,. Phosphodiesterase inhibitors in inflammatory bowel disease. Expert. Opin. Investig. Drugs 2012, 21, 261.
8. J. M. Michalski, G. Golden, J. Ikari, S. I. Rennard,. PDE4: a novel target in the treatment of chronic obstructive pulmonary disease. Clin. Pharmacol. Ther. 2012, 91, 134.
9. Z. Diamant, D. Spina,. PDE4 inhibitors: a novel, targeted therapy for obstructive airways disease. Pul. Pharmacol. Ther. 2011, 24, 353.
10. M. A. Giembycz,. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert. Opin. Investig. Drugs 2001, 10, 1361.
11. W. Krause, G. Kuhne,. Biotransformation of the antidepressant D,L-rolipram. II. Metabolite patterns in man, rat, rabbit, rhesus and cynomolgus monkey. Xenobiotica 1993, 23, 1277.
12. W. Krause, G. Kuhne, U. Jakobs, G. A. Hoyer,. Biotransformation of the antidepressant DL-rolipram. I. Isolation and identification of metabolites from rat, monkey, and human urine. Drug Metab. Dispos. 1993, 21, 682.
13. T. D. Bethke, M. Hartmann, A. Hunnemeyer, G. Lahu, C. H. Gleiter,. Influence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center study. Int. J. Clin. Pharmacol. Ther. 2011, 49, 491.
14. T. D. Bethke, G. Lahu,. High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast. Int. J. Clin. Pharmacol. Ther. 2011, 49, 51.
15. N. G. Knebel, R. Herzog, F. Reutter, K. Zech,. Sensitive quantification of roflumilast and roflumilast N-oxide in human plasma by LC-MS/MS employing parallel chromatography and electrospray ionisation. J. Chromatogr. B 2012, 893-894, 82.
16. S. Beuck, W. Bornatsch, A. Lagojda, W. Schänzer, M. Thevis,. Development of liquid chromatography-tandem mass spectrometry-based analytical assays for the determination of HIF stabilizers in preventive doping research. Drug Test. Anal. 2011, 3, 756.
17. S. Beuck, W. Schänzer, M. Thevis,. Investigation of the in vitro metabolism of the emerging drug candidate S107 for doping-preventive purposes. J. Mass Spectrom. 2011, 46, 112.
18. M. Thevis,. Mass Spectrometry in Sports Drug Testing-Characterization of Prohibited Substances and Doping Control Analytical Assays. John Wiley, Hoboken, 2010.
19. M. Thevis, S. Guddat, W. Schänzer,. Doping control analysis of trenbolone and related compounds using liquid chromatography-tandem mass spectrometry. Steroids 2009, 74, 315.
20. International Conference on Harmonisation, 2004. http://www.fda.gov/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm265700.htm (accessed 7 March 2013).
21. J. Mandel,. The Statistical Analyses of Experimental Data. John Wiley, New York, 1964.
22. V. H. Wysocki, G. Tsaprailis, L. L. Smith, L. A. Breci,. Mobile and localized protons: a framework for understanding peptide dissociation. J. Mass Spectrom. 2000, 35, 1399.
23. U. Mareck, M. Thevis, S. Guddat, A. Gotzmann, M. Bredehöft, H. Geyer, W. Schänzer, in Recent Advances in Doping Analysis, vol. 12, (Eds:, W. Schänzer, H. Geyer, A. Gotzmann, U. Mareck,). Sport und Buch Strauss, Cologne, 2004, p. 65.
24. M. Thevis, A. Thomas, W. Schänzer,. Current role of LC-MS(/MS) in doping control. Anal. Bioanal. Chem. 2011, 401, 405.
25. World Anti-Doping Agency, 2013. http://www.wada-ama.org/en/World-Anti- Doping-Program/Sports-and-Anti-Doping-Organizations/International-Standards/ Prohibited-List/ (accessed 7 January 2013).